Session 2: Company-Specific Data on Cycled Resin Testing

References

1. 1.↵
   International Conference on Harmonisation (ICH). Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; Q5A(R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: Geneva, Switzerland, 1998. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5A_R1/Step4/Q5A_R1__Guideline.pdf.
2. 2.↵
   1. Remington K. M.

   Fundamentals Of Viral Clearance Studies Part 4 – Considerations For Evaluating Viral Clearance By Chromatography Steps. Bioresearch Online 2013, 1–2.
3. 3.↵
   1. Brorson K.,
   2. Brown J.,
   3. Hamilton E.,
   4. Stein K. E.

   Identification of Protein A Media Performance Attributes That Can Be Monitored as Surrogates for Retrovirus Clearance during Extended Re-use. J. Chromatogr. A 2003, 989 (1), 155–163.

   OpenUrlPubMed
4. 4.↵
   1. Lute S.,
   2. Norling L.,
   3. Hanson M.,
   4. Emery R.,
   5. Stinson D.,
   6. Padua K.,
   7. Blank G.,
   8. Chen Q.,
   9. Brorson K.

   Robustness of Virus Removal by Protein A Chromatography Is Independent of Media Lifetime. J. Chromatogr. A 2008, 1205 (1-2), 17–25.

   OpenUrlPubMed
5. 5.↵
   1. Zhang M.,
   2. Lute S.,
   3. Norling L.,
   4. Hong C.,
   5. Safta A.,
   6. O'Connor D.,
   7. Bernstein L. J.,
   8. Wang H.,
   9. Blank G.,
   10. Brorson K.,
   11. Chen Q.

   A Novel, Q-PCR Based Approach to Measuring Endogenous Retroviral Clearance by Capture Protein A Chromatography. Biotechnol. Bioeng. 2009, 102 (5), 1438–1447.

   OpenUrlPubMed
6. 6.↵
   1. Kelley B. D.,
   2. Tannatt M.,
   3. Magnusson R.,
   4. Hagelberg S.,
   5. Booth J.

   Development and Validation of an Affinity Chromatography Step Using a Peptide Ligand for cGMP Production of Factor VIII. Biotechnol. Bioeng. 2004, 87 (3), 400–412.

   OpenUrlPubMed
7. 7.↵
   1. Morrica A.,
   2. Nardini C.,
   3. Falbo A.,
   4. Bailey A. C.,
   5. Bucci E.

   Manufacturing Process of Anti-thrombin III Concentrate: Viral Safety Validation Studies and Effect of Column Re-use on Viral Clearance. Biologicals 2003, 31 (3), 165–173.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Andersson I.,
   2. Connor S. E.,
   3. Lindquist L. O.,
   4. Watson E. A.

   Validation Study for the Removal/Inactivation of Viruses during a Chromatographic Purification Process for Albumin and IgG. 24th Conference of the International Society of Blood Transfusion, 1996.
9. 9.↵
   1. Xie Y.-W.,
   2. Chan P. K.,
   3. Szeto C. K.,
   4. Kwok S. Y.,
   5. Chu I. M.,
   6. Chu S. S.,
   7. Cheung J. L.,
   8. Wong S. W.,
   9. Ali M.

   B; Wong, B. L. Clearance of Dengue Virus in the Plasma-derived Therapeutic Proteins. Transfusion 2008, 48 (7), 1342–1347.

   OpenUrl
10. 10.↵
    1. Norling L.,
    2. Lute S.,
    3. Emery R.,
    4. Khuu W.,
    5. Voisard M.,
    6. Xu Y.,
    7. Chen Q.,
    8. Blank G.,
    9. Brorson K.

    Impact of Multiple Re-use of Anion-Exchange Chromatography Media on Virus Removal. J. Chromatogr. A 2005, 1069 (1), 79–89.

    OpenUrlPubMed
11. 11.↵
    1. Kelley B. D.,
    2. Jakubik J.,
    3. Vicik S.

    Viral Clearance Studies on New and Used Chromatography Resins: critical Review of a Large Dataset. Biologicals 2008, 36 (2), 88–98.

    OpenUrlPubMed
12. 12.↵
    1. Curtis S.,
    2. Lee K.,
    3. Blank G. S.,
    4. Brorson K.,
    5. Xu Y.

    Generic/Matrix Evaluation of SV40 Clearance by Anion Exchange Chromatography in Flow-through Mode. Biotechnol. Bioeng. 2003, 84 (12), 179–186.

    OpenUrlPubMed
13. 13.↵
    1. Bach J.,
    2. Connell-Crowly L.

    Clearance of the Rodent Retrovirus, XMuLV, by Protein A Chromatography. Biotechnol. Bioeng. 2014, 112 (4), 743–750.

    OpenUrl